Editorial
doi: 10.1002/art.41203.
Epub 2020 Apr 23.
Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States
Affiliations
- PMID: 31922346
- PMCID: PMC7255927
- DOI: 10.1002/art.41203
Item in Clipboard
Editorial
Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States
Arthritis Rheumatol.
2020 Jun.
No abstract available
Comment on
-
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.Arthritis Rheumatol. 2020 Jun;72(6):1036-1038. doi: 10.1002/art.41201. Epub 2020 Apr 7. Arthritis Rheumatol. 2020. PMID: 31943866 No abstract available.
Similar articles
-
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.Arthritis Rheumatol. 2020 Jun;72(6):1036-1038. doi: 10.1002/art.41201. Epub 2020 Apr 7. Arthritis Rheumatol. 2020. PMID: 31943866 No abstract available.
-
First biosimilar drug approved for sale in the United States.J Natl Cancer Inst. 2015 Jul 3;107(7):djv191. doi: 10.1093/jnci/djv191. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 26142444 No abstract available.
-
US rheumatologists' beliefs and knowledge about biosimilars: a survey.Rheumatology (Oxford). 2021 Feb 1;60(2):896-901. doi: 10.1093/rheumatology/keaa502. Rheumatology (Oxford). 2021. PMID: 33146388 Free PMC article.
-
A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.Immunotherapy. 2018 Feb;10(2):107-117. doi: 10.2217/imt-2017-0107. Epub 2017 Nov 10. Immunotherapy. 2018. PMID: 29124994 Review.
-
Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.Am J Clin Dermatol. 2020 Aug;21(4):483-491. doi: 10.1007/s40257-020-00507-1. Am J Clin Dermatol. 2020. PMID: 32048187 Review.
Cited by
-
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.BioDrugs. 2023 May;37(3):409-420. doi: 10.1007/s40259-023-00589-3. Epub 2023 Mar 23. BioDrugs. 2023. PMID: 36952213 Free PMC article.
-
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.BioDrugs. 2025 Jul;39(4):537-553. doi: 10.1007/s40259-025-00727-z. Epub 2025 Jun 5. BioDrugs. 2025. PMID: 40473917 Free PMC article. Review.
-
Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.World J Clin Cases. 2022 May 16;10(14):4327-4333. doi: 10.12998/wjcc.v10.i14.4327. World J Clin Cases. 2022. PMID: 35663066 Free PMC article. Review.
-
Sustainable menaquinone-7 production through continuous fermentation in biofilm bioreactors.Bioprocess Biosyst Eng. 2024 Jul;47(7):1107-1116. doi: 10.1007/s00449-024-03040-1. Epub 2024 Jun 12. Bioprocess Biosyst Eng. 2024. PMID: 38864863
-
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20964031. doi: 10.1177/1759720X20964031. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 33133246 Free PMC article.
References
-
- Brill A, Ippolito B. The Economics of Biologic Drugs: A Further Response to Bach et al., Health Affairs Blog, August 8, 2019.
-
- Jensen TB, Bartels D, Sædder EA et al. Eur J Clin Pharmacol (2019).
-
- Use of Step Through Policies for Competitive Biologics Among Commercial U.S. Insurers. Avalere Health. May 2018. https://avalere.com/insights/use-of-step-through-policies-for-competitiv.... Accessed December 8, 2019.
-
- Price WN, Rai AK How logically impossible patents block biosimilars. Nat Biotechnol 37, 862–863 (2019). - PubMed
-
- Overpatented and Overpriced. http://www.i-mak.org/wp-content/uploads/2018/09/i-mak.humira.report.fina.... Accessed December 8, 2019.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
